


R715

Cat. No.: HY-103290
CAS No.: 185052-09-9
Molecular Formula: C₅₇H₈₁N₁₃O₁₂
Molecular Weight: 1140.33
Sequence: Ac-Lys-Arg-Pro-Pro-Gly-Phe-Ser-[d-βNal]-Ile
Sequence Shortening: Ac-KRPPGFS-[d-βNal]-I
Target: Bradykinin Receptor
Pathway: GPCR/G Protein
Storage: Sealed storage, away from moisture
 Powder -80°C 2 years
 -20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (87.69 mM; Need ultrasonic)			
	Solvent Concentration	Mass 1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	0.8769 mL	4.3847 mL	8.7694 mL
	5 mM	0.1754 mL	0.8769 mL	1.7539 mL
	10 mM	0.0877 mL	0.4385 mL	0.8769 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice ^[1] .
-------------	---

REFERENCES

[1]. Gabra BH, et al. Beneficial effect of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice. *Peptides*. 2003;24(8):1131-1139.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA